Department of Vermont Health Access
Pharmacy Benefits Management Program

DUR Board Meeting Agenda

January 17th 6:00 – 8:30 p.m.

- Executive Session 6:00 - 6:30
- Introductions and Approval of DUR Board Minutes 6:30 - 6:35
  (Public Comment Prior to Board Action)
- DVHA Pharmacy Administration Updates 6:35 - 6:40
  - Discussion of Act 172, Sec. E.306.11: Prescribing Practices;
    Drug Utilization Review Board; Report
- Medical Director Update 6:40 – 6:45
  - Clinical Programs Update
  - Prescriber Comments
- Follow-up Items from Previous Meetings 6:45 – 6:45
- RetroDUR/DUR 6:45 – 7:00
  - Introduce: Long Term use of Skeletal Muscle Relaxants
  - Data presentation: Compliance with GLP-1 Agonists
    in Type II Diabetes
- Review of Newly-Developed/Revised 7:00 – 7:00
  (Public comment prior to Board action)
- Clinical Update: Drug Reviews 7:00 – 7:45
  (Public comment prior to Board action)

Abbreviated New Drug Reviews
- None

Full New Drug Reviews
- Afstyla® (antihemophilic factor, recombinant) (included in the Hemophilia Factor
  Therapeutic Drug Class Review)
- Bevespi® Aero (glycopyrrolate/formoterol)
- Briviact® (brivaracetam)
- Jentadueto® XR (linagliptin & metformin extended-release)
- Nuplazid® (pimavanserin)
- Probuphine® (buprenorphine) (included in the Opiate Dependence Agents
  Review)
- Vonvendi® (von Willebrand factor, recombinant) (included in the Hemophilia Factor
  Therapeutic Drug Class Review)
- Xiidra® (lifitegrast)
- Xtampza® ER (oxycodone extended-release)

- **New Managed Therapeutic Drug Classes**
  (Public comment prior to Board action)

- **Therapeutic Drug Classes – Periodic Review**
  (Public comment prior to Board action)
  - Androgenic Agents
  - Antifungals, Topical
  - Anti-parasitics, Topical
  - Antivirals, Oral
  - Antivirals, Topical
  - Atopic, Dermatitis
  - Hemophilia Factor
  - H. Pylori
  - Opiate Dependence Agents

- **Review of Newly-Developed/Revised**
  (Public comment prior to Board action)

- **General Announcements**
  (Public comment prior to Board action)

- **Selected FDA Safety Alerts**
  - Products Containing Belladonna Extract by Raritan Pharmaceuticals: Recall - Possible Belladonna Alkaloids
  - General Anesthetic and Sedation Drugs: Drug Safety Communication - New Warnings for Young Children and Pregnant Women
  - FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes

- **Adjourn**
  8:30